Skip to Main Content

Paper Details

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Int J Cancer
15
2022
BC, CDK4/6i, Cancer, Cyclin-dependent-kinase-4/6, HER2, HR, Palbociclib, advanced hormone, breast cancer, metastatic breast cancer, palbociclib, patients
Author NameAffiliation
Min Jin HaThe University of Texas MD Anderson Cancer Center
Min Jin HaGraduate School of Public Health, Yonsei University
Qingyi WeiThe University of Texas MD Anderson Cancer Center
Yu ShenThe University of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2